Cargando…
Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study
BACKGROUND: Granulocyte and monocyte apheresis (GMA) has shown therapeutic efficacy in active ulcerative colitis (UC). We thought that in patients with pouchitis after proctocolectomy for UC, GMA might produce immunological effects in the intestinal mucosa, and improve clinical symptoms. This prospe...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298477/ https://www.ncbi.nlm.nih.gov/pubmed/28203278 http://dx.doi.org/10.1177/1756283X16679348 |
_version_ | 1782505874113167360 |
---|---|
author | Yamamoto, Takayuki Tanaka, Toshiaki Yokoyama, Tadashi Shimoyama, Takahiro Ikeuchi, Hiroki Uchino, Motoi Watanabe, Toshiaki |
author_facet | Yamamoto, Takayuki Tanaka, Toshiaki Yokoyama, Tadashi Shimoyama, Takahiro Ikeuchi, Hiroki Uchino, Motoi Watanabe, Toshiaki |
author_sort | Yamamoto, Takayuki |
collection | PubMed |
description | BACKGROUND: Granulocyte and monocyte apheresis (GMA) has shown therapeutic efficacy in active ulcerative colitis (UC). We thought that in patients with pouchitis after proctocolectomy for UC, GMA might produce immunological effects in the intestinal mucosa, and improve clinical symptoms. This prospective study was to evaluate the efficacy of GMA for antibiotic-refractory pouchitis after proctocolectomy for UC. METHODS: A total of 13 patients with pouchitis disease activity index (PDAI) > 7 unresponsive to 2 weeks of antibiotic therapy were included. All patients received 10 GMA sessions at 2 sessions/week over 5 consecutive weeks. The primary endpoints were response (a decrease of ⩾3 points in the PDAI) and remission (PDAI < 4). Secondary endpoints included reduction of white blood cells (WBCs), C-reactive protein (CRP), faecal markers (calprotectin and lactoferrin), reduction of the PDAI endoscopic subscore, and GMA safety. RESULTS: The median PDAI score was significantly decreased from 11 (range, 9–15) at entry to 9 (range, 6–13) after the GMA therapy (p = 0.02). A total of six patients (46%) responded to the treatment, but none achieved remission. The median endoscopic subscore (maximum: 6) was 5 (range, 4–6) at entry and 5 (range, 1–6) after the treatment (p = 0.10). None of the laboratory markers (WBCs, CRP, faecal calprotectin and lactoferrin) significantly changed during the treatment. Transient adverse events (AEs) were observed in two patients (15%), dyspnoea in one and headache in one. The AEs were not serious, and all patients completed the 10 GMA sessions. CONCLUSIONS: GMA has a good safety profile, but its efficacy appears to be limited in the management of chronic refractory pouchitis. However, a large controlled study should be conducted to evaluate the efficacy of GMA therapy in patients with pouchitis at an earlier clinical stage, before the disease has become refractory to conventional medical therapy. |
format | Online Article Text |
id | pubmed-5298477 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-52984772017-02-15 Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study Yamamoto, Takayuki Tanaka, Toshiaki Yokoyama, Tadashi Shimoyama, Takahiro Ikeuchi, Hiroki Uchino, Motoi Watanabe, Toshiaki Therap Adv Gastroenterol Original Research BACKGROUND: Granulocyte and monocyte apheresis (GMA) has shown therapeutic efficacy in active ulcerative colitis (UC). We thought that in patients with pouchitis after proctocolectomy for UC, GMA might produce immunological effects in the intestinal mucosa, and improve clinical symptoms. This prospective study was to evaluate the efficacy of GMA for antibiotic-refractory pouchitis after proctocolectomy for UC. METHODS: A total of 13 patients with pouchitis disease activity index (PDAI) > 7 unresponsive to 2 weeks of antibiotic therapy were included. All patients received 10 GMA sessions at 2 sessions/week over 5 consecutive weeks. The primary endpoints were response (a decrease of ⩾3 points in the PDAI) and remission (PDAI < 4). Secondary endpoints included reduction of white blood cells (WBCs), C-reactive protein (CRP), faecal markers (calprotectin and lactoferrin), reduction of the PDAI endoscopic subscore, and GMA safety. RESULTS: The median PDAI score was significantly decreased from 11 (range, 9–15) at entry to 9 (range, 6–13) after the GMA therapy (p = 0.02). A total of six patients (46%) responded to the treatment, but none achieved remission. The median endoscopic subscore (maximum: 6) was 5 (range, 4–6) at entry and 5 (range, 1–6) after the treatment (p = 0.10). None of the laboratory markers (WBCs, CRP, faecal calprotectin and lactoferrin) significantly changed during the treatment. Transient adverse events (AEs) were observed in two patients (15%), dyspnoea in one and headache in one. The AEs were not serious, and all patients completed the 10 GMA sessions. CONCLUSIONS: GMA has a good safety profile, but its efficacy appears to be limited in the management of chronic refractory pouchitis. However, a large controlled study should be conducted to evaluate the efficacy of GMA therapy in patients with pouchitis at an earlier clinical stage, before the disease has become refractory to conventional medical therapy. SAGE Publications 2016-11-25 2017-02 /pmc/articles/PMC5298477/ /pubmed/28203278 http://dx.doi.org/10.1177/1756283X16679348 Text en © The Author(s), 2016 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Yamamoto, Takayuki Tanaka, Toshiaki Yokoyama, Tadashi Shimoyama, Takahiro Ikeuchi, Hiroki Uchino, Motoi Watanabe, Toshiaki Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study |
title | Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study |
title_full | Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study |
title_fullStr | Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study |
title_full_unstemmed | Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study |
title_short | Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study |
title_sort | efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298477/ https://www.ncbi.nlm.nih.gov/pubmed/28203278 http://dx.doi.org/10.1177/1756283X16679348 |
work_keys_str_mv | AT yamamototakayuki efficacyofgranulocyteandmonocyteapheresisforantibioticrefractorypouchitisafterproctocolectomyforulcerativecolitisanopenlabelprospectivemulticentrestudy AT tanakatoshiaki efficacyofgranulocyteandmonocyteapheresisforantibioticrefractorypouchitisafterproctocolectomyforulcerativecolitisanopenlabelprospectivemulticentrestudy AT yokoyamatadashi efficacyofgranulocyteandmonocyteapheresisforantibioticrefractorypouchitisafterproctocolectomyforulcerativecolitisanopenlabelprospectivemulticentrestudy AT shimoyamatakahiro efficacyofgranulocyteandmonocyteapheresisforantibioticrefractorypouchitisafterproctocolectomyforulcerativecolitisanopenlabelprospectivemulticentrestudy AT ikeuchihiroki efficacyofgranulocyteandmonocyteapheresisforantibioticrefractorypouchitisafterproctocolectomyforulcerativecolitisanopenlabelprospectivemulticentrestudy AT uchinomotoi efficacyofgranulocyteandmonocyteapheresisforantibioticrefractorypouchitisafterproctocolectomyforulcerativecolitisanopenlabelprospectivemulticentrestudy AT watanabetoshiaki efficacyofgranulocyteandmonocyteapheresisforantibioticrefractorypouchitisafterproctocolectomyforulcerativecolitisanopenlabelprospectivemulticentrestudy |